The Road Less Traveled to Fusion Energy

The Road Less Traveled to Fusion Energy

The modern quest for Promethean fire is underway in an anonymous office park in Foothill Ranch, California, an hour southeast of Los Angeles. In the park, along a meandering drive, you will find a huge, modern warehouse building with “TAE Technologies” emblazoned on the door. Inside, you will find a 100-foot-long, $200 million fusion-energy experiment named Norman. And in a second-floor office, upstairs from that looming machine, you will find the would-be Prometheus himself: Michl Binderbauer, TAE’s boyish-looking and relentlessly upbeat co-founder and CEO.

TAE Life Sciences secures $30M in initial B round to accelerate development of unique boron delivery drugs for novel cancer treatment, boron neutron capture therapy (BNCT).

TAE Life Sciences secures $30M in initial B round to accelerate development of unique boron delivery drugs for novel cancer treatment, boron neutron capture therapy (BNCT).

TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy solutions (BNCT), announced the launch of an innovative in-house boron delivery drug development program supported by an influx of $30M in funding. The initial phase of the B-round funds comes from a consortium of investors including ARTIS Ventures, who led the company’s initial funding in 2018.

What’s Clean, Green and Combats Climate Change?

What’s Clean, Green and Combats Climate Change?

As CEO of TAE Technologies, the world’s largest private fusion reactor company, Michl Binderbauer is one of those who believes that fusion power could be on the near horizon – and is using artificial intelligence co-developed with Google to help make it a reality.

The Future Looks Bright

The Future Looks Bright

The Future Looks Bright: CEO Michl Binderbauer reflects on the last 20 years of TAE Technologies and what the new decade holds for fusion research and more.